Introduction
Prostate cancer is one of the most commonly diagnosed cancers among men worldwide with a signifi cant difference in incidence rates among the world's geographic regions; during the past 15 years, it has become an important concern of public health (1) . The highest incidence has been reported in the Scandinavian countries, with an intermediate incidence being reported in the United States and the United Kingdom and the lowest being in the Far East, especially in China and Japan (2) . In the United States and Sweden, prostate cancer is the most common cancer of all malignancies, ahead of lung cancer (3) . In 2008, around 338 000 men were diagnosed with prostate cancer in Europe (4). The lowest European incidence rates are in Southern and Eastern Europe, and the highest rates are found in Northern and Western Europe (Fig. 1) . Prostate cancer is the second most commonly diagnosed malignancy in men after lung cancer in Latvia (Fig. 2) .
The prevalence and incidence rates for prostate cancer in Latvia are increasing year by year: from 1813 cases in 2000 to 4850 cases in 2010 and from 522 cases in 2000 to 855 cases in 2010, respectively (Fig. 3) . Despite a wide range of diagnostic measures and aggressive treatment, the mortality rate from prostate cancer has not changed signifi cantly and is one of the major causes of death among men in Latvia.
Progression of prostate cancer is a complex interaction of molecular, environmental, and possibly social factors (5) . Family cancer history is an important screening tool for identifi cation of high-risk patients groups with inherited cancer. It is important to differentiate molecular and environmental risk factors affecting the progression of prostate cancer, and family cancer history is a helpful tool that captures some of these risk aspects (6) . Although environment, diet, lifestyle, sex hormones, and genetic predisposition of individuals are all risk factors for prostate cancer, a positive family history of prostate cancer is the most important clinical risk factor. According to a Nordic study of twins, hereditary factors play a much greater role in the etiology of prostate cancer than in that of any other malignancy (7) .
Many studies on several alleles indicate the conferring of dominantly inherited susceptibility for prostate cancer with high penetrance, causing multiple cases of prostate cancer in a family. However, Fig. 1 Genome research is a complex and time-consuming process. Revealing the most frequent mutations in the Latvian population could considerably improve the presymptomatic diagnosis of prostate cancer. As no detailed studies have been done in Latvia, the aim of the present study was to evaluate the epidemiological features and molecular basis of hereditary prostate cancer in Latvia, and to consider the clinical implications of our fi ndings.
Material and Methods
This was a prospective study involving 1217 patients with newly diagnosed prostate cancer from all regions of Latvia identifi ed at the largest oncology hospitals. All patients for our study were selected and identifi ed from November 2003 to March 2011.
All patients were enrolled in the study regardless of TNM stage, Gleason's score, ethnicity, or health status.
Data on clinical characteristics including age at diagnosis, individual nationality, and family cancer history were collected using a standardized questionnaire previously tested in hospital-and population-based screening (14, 15) . Prostate cancer patients were asked if their blood relatives had had any malignancy. Further, information on cancer localization, age of cancer diagnosis, and age at death, if applicable, was collected. Completed questionnaires were analyzed separately depending on positive (at least one malignancy of any localization among blood relatives) or negative (no malignancy among blood relatives) data of family cancer history. Table 1 summarizes the characteristics of patients with prostate cancer by age groups in association with a family history of prostate cancer. Family cancer histories matching hereditary cancer syndrome were analyzed according to the clinical diagnostic criteria of hereditary prostate cancer ( Table 2 ). All patients were invited for additional consultation and were offered molecular diagnostics. If patients agreed, peripheral venous blood samples were collected. Molecular examination was performed for the fi rst 280 prostate cancer patients and 173 control cases for the founder mutation 657del5 of the NBS1 gene and 68 prostate cancer patients for the founder mutations 300T/G, 4153delA, and 5382insC of the BRCA1 gene if any case of breast or ovarian cancer was observed in their family. Blood samples of the control group were collected from the clamped distal part of the umbilical cord in consecutive anonymous newborns.
Statistical data analysis was carried out with the CIA (DOS program Confi dence Interval Analysis) 
Results
In total, 1217 family cancer histories were analyzed; 640 families (52.6%; 95% CI, 49.8% to 55.4%) were found to have a positive family history of cancer, and 577 families (47.4%; 95% CI, 44.6% to 50.2%) had no family cancer history. Our series showed the relationship between family cancer history and age at the onset of prostate cancer: individuals with a positive family history of cancer were younger at the onset of prostate cancer than individuals with a negative family history of cancer (Fig. 4) .
Of Equally, a founder mutation of the NBS1 gene was detected in 1 (0.4%; 95% CI, 0.1% to 2.0%) of the 280 cases in the prostate cancer group and in 1 (0.6%; 95% CI, 0.1% to 3.2%) of the 173 cases in the control group. The individual from the prostate cancer group was a 68-year-old male with a negative family history of cancer. As the control group data were anonymous, no data concerning family cancer history were available.
Of the 112 samples analyzed in the prostate cancer group, 2 cases (1.8%; 95% CI, 0.5% to 6.3%) of 5382insC mutation of the BRCA1 gene were iden- 
Discussion
Although it is thought that 5% to 10% of prostate cancer cases are hereditary (17) , our study revealed a relatively low proportion of families with defi nitive inheritance and high proportion of families with suspected inheritance (1.3% vs. 14.1%). As clinical defi nition of hereditary prostate cancer is based on the data of family cancer history, any missing part of information is critical. Therefore, any family with no other malignancies among relatives should be carefully evaluated and considered as incomplete as data could be missing due to loss of contact during wartime, deportation, and migration in the middle of the 20th century in Latvia.
Except for younger age at diagnosis, no phenotypic features have been clearly associated with hereditary prostate cancer (18) . Our data did not reveal a signifi cant difference in the median age at diagnosis of prostate cancer comparing the defi nitive and suspected hereditary pros tate cancer groups. The molecular pathology of prostate cancer is complex; not only multiple genes are involved in its pathogenesis, but additional environmental factors as well (5) . The BRCA1, BRCA2, NBS1, and CHEK2 genes have been only recently identifi ed as possible prostate cancer susceptibility genes. ELAC2 was the fi rst hereditary prostate cancer susceptibility gene identifi ed, and subsequent studies have not confi rmed the evidence for its role in prostate cancer (19) . Therefore, it is not possible to comment on the importance of these genes in hereditary prostate cancer until additional confi rmatory studies have been performed.
A study from southern Sweden (n=356) revealed that 15% of patients with prostate cancer had at least 1 case of prostate cancer among their brothers or fathers. Based on the family history, 3.1% were classifi ed as having hereditary prostate cancer. Fur- thermore, this proportion was signifi cantly higher among patients diagnosed before the age of 60 years than among older patients (7.1% vs. 2.2%) (20) .
A systematic genealogy study from France (n=691) confi rmed the data of earlier studies, revealing a 3.6% prevalence of hereditary forms of prostate cancer. Analysis of the results according to the age at diagnosis of prostate cancer showed a higher incidence of hereditary forms occurring at younger age, i.e., before the age of 65 years. Similarly, the study confi rmed the earlier onset of prostate cancer in patients with a genetic predisposition (21) .
Both positive and negative studies have been published showing the increased risk of prostate cancer in BRCA1 and BRCA2 mutation carriers (22) (23) (24) . To establish the infl uence of the BRCA1 gene, 1793 men with prostate cancer and 4570 controls were genotyped for founder mutations (C61G, 4153delA, and 5382insC) in Poland. The results showed a higher frequency of the 4153delA mutation in prostate cancer cases (0.22%) than controls (0.04%). Data suggest that the 5382insC mutation is unlikely to be pathogenic for prostate cancer in the Polish population as it was more frequently present in the control population than in the prostate cancer group (25) . In our study, of the 68 individuals analyzed, only 1 case was found to carry the mutation 5382insC in the BRCA1 gene. This may be explained by the high proportion of the Slavic population in Latvia. Although there are data confi rming a more aggressive prostate cancer phenotype for BRCA1 and BRCA2 mutation carriers, it was not considered for analysis in our study as the number of cases was limited (26, 27) .
A recent study has reported that BRCA2 carriers with prostate cancer have a poorer survival rate than noncarrier with prostate cancer. In this study, the survival rate of men with the BRCA2 mutation and prostate cancer (n=182) was compared with that of men with the BRCA1 mutation and prostate cancer (n=119). The median survival rate from diagnosis was 4.0 years for men with the BRCA2 mutation and 8.0 years for men with the BRCA1 mutation, with a highly signifi cant difference (28) .
The frequency of the NBS1 gene mutation in the German population is 1 per 866 people (29) . In comparison, a remarkably high carrier frequency of the 657del5 mutation in the NBS1 gene was detected in the Slavic populations: 1 per 154 in the Czech Republic, 1 per 190 in Poland, and 1 per 182 in Ukraine (30) . Our data failed to support the involvement of the NBS1 gene in our prostate cancer cases, as no statistically signifi cant difference between the prostate cancer and control groups was detected in Latvia (1 per 280 vs. 1 per 173) . This supports previous studies and confi rms geographical and racial differences among populations.
Conclusions
Increased incidence rates for prostate cancer in Latvia may be the result of improved detection and better awareness of the disease rather than a true increase in the prevalence of the disease. Our study did not reveal predisposition genes for hereditary prostate cancer as the founder mutations of the BRCA1 and NBS1 genes are rarely detected in Latvia. We observed a insignifi cant difference in the frequency of BRACA1 and NBS1 founder mutations between prostate cancer and the control group; this may be explained by geographical differences and the relatively high proportion of mixed ethnic groups in Latvia. Our epidemiological series show a lower incidence of hereditary prostate cancer in Latvia compared with the data from other populations. The main reason affecting this may be an incomplete family cancer history due to the loss of contact with relatives.
This emphasizes the importance of evaluation of family cancer history as individuals with a positive family history of cancer (at least one malignancy of any localization among blood relatives) have an earlier onset of prostate cancer than individuals with a negative family history of cancer (no malignancy cases among blood relatives).
